CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a ...

Carl Spana; President, Chief Executive Officer, Director; Palatin Technologies Inc Stephen Wills; Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary ...

Pursuant to the completion of the sale of Vyleesi’s worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171M in December 2023, Palatin (PTN) did not record any ...

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is ...

CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

(RTTNews) - Palatin Technologies, Inc. (PTN), a biopharmaceutical company, on Thursday announced the completion of its Phase 2 BMT-801 clinical study evaluating the combination of MC4R ...

Fair Value Adjustment Loss: $8.1 million for the quarter ended December 31, 2024. Palatin Technologies Inc (PTN) reported a significant decrease in net cash used in operations, from $10.5 million ...